Acknowledgement email

Email	s11C [redacted]
Email from	adr.reports@health.gov.au
Email cc	
Subject	TGA Adverse Event (AE) Report s11C [redacted] [SEC=OFFICIAL]
Date and Time	27/07/2022 03:59:05 PM
Attachments	s11C [redacted]

Dear This email is related to your submission to the TGA's Australian Adverse Event Management System (AEMS). Please refer to the attachments.

Australian Government

Department of Health
Therapeutic Goods Administration

[redacted]

Email Address: [redacted]

Dear Sir/Madam

Re: TGA AE Reference: s11C [redacted]
Drug: Covishield Vaxzevria (ChAdOx1-S, Oxford/AstraZenec
Your Reference: [redacted]

Thank you for submi. ng your adverse event report, which was entered into the Therapeutic Goods Administration's (TGA)'s Adverse Event Management System (AEMS) on 27/7/2022. This report has been identified as a duplicate of AE Report Number [redacted] which is the active number for this case. If you submit any further information, please quote the active TGA AE reference number allocated.

Please refer to the Privacy Statement at the end of this letter for information about how the TGA handles information of this kind. The TGA does not include any personal information in our database that may have been inadvertently provided in the report, such as patient names but does keep information on the Sender of the report in case any clarification is needed.

The TGA undertakes regular analysis of the AEMS to identify new and emerging safety issues (signals) that may be related to medicines in use in Australia. When a signal is detected, further review is undertaken by the TGA to determine whether any action is required - such as changes to Product Information (PI), labelling or packaging, recall of a product or provision of information on the issue to prescribers and consumers of a medicine, including the issuing of Alerts.

Further information about medicines, such as Product Information, Consumer Medicine Information and Alerts can be found on the TGA website at http://www.tga.gov.au.

If you wish to receive regular updates about Safety Information on medicines and devices you can subscribe to our notification system. Information about subscribing can be found at http://www.tga.gov.au/newsroom/subscribe-rss.htm.Thank you in anticipation of your ongoing assistance.

This is an automatically generated acknowledgment letter. There is no need to respond to this correspondence. Any enquiries about this report should be directed to adr.reports@health.gov.au.

Yours sincerely,

The Adverse Event & Medicine Defect Section
on behalf of the Head
Pharmacovigilance Branch
27/7/2022

PRIVACY STATEMENT
For general privacy information, go to www.tga.gov.au/about/website-privacy.htm.

Information provided in your report is collected to assist in the post market monitoring of the safety of therapeutic goods under the *Therapeutic Goods Act 1989* (the Act). All reports are entered into the Therapeutic Goods Administration's (TGA's) Australian Adverse Event Management System. Further information about how the TGA uses adverse event information that is reported to it is available at https://www.tga.gov.au/reporting-adverse-events.

The TGA collects personal information in this report to:
• Monitor the safety of medicines and vaccines under the Act.
• Contact the reporter of the adverse event if further information is required.
• Contact representatives of entities that supply therapeutic goods, to discuss reported adverse events.
• Check that the same information has not been received multiple times for the same adverse event.

At times, adverse event information is collected from someone other than the individual to whom the personal information relates. This can occur when an adverse event is reported to a person or an entity other than the TGA (such as a health professional or a hospital or a sponsor), and that person or entity passes the information on to the TGA. In those cases, the TGA will not collect the name and contact details of patients. However, the TGA may collect other information relating to patients including the date of birth or age, gender, weight, initials and information about the relevant adverse event.

Personal information collected in your report may be used or disclosed as permitted under the Privacy Act 1988, including by consent or where the disclosure is required by, or authorised under, a law (for example, under section 61 of the Act). Where a report relates to vaccine events, any personal information in the adverse event report may be disclosed to State and Territory health agencies under section 61(3) of the Act.

Australian Government
Department of Health
Therapeutic Goods Administration

[redacted]

Email Address: [redacted]

Dear Sir/Madam

Re: TGA AE Reference: s11C [redacted]
Drug: Covishield Vaxzevria (ChAdOx1-S, Oxford/AstraZenec
Your Reference: [redacted]

Thank you for submitting your adverse event report, which was entered into the Therapeutic Goods Administration's (TGA)'s Adverse Event Management System (AEMS) on 27/7/2022. This report has been identified as a duplicate of AE Report Number [redacted] which is the active number for this case. If you submit any further information, please quote the active TGA AE reference number allocated.

Please refer to the Privacy Statement at the end of this letter for information about how the TGA handles information of this kind. The TGA does not include any personal information in our database that may have been inadvertently provided in the report, such as patient names but does keep information on the Sender of the report in case any clarification is needed.

The TGA undertakes regular analysis of the AEMS to identify new and emerging safety issues (signals) that may be related to medicines in use in Australia. When a signal is detected, further review is undertaken by the TGA to determine whether any action is required - such as changes to Product Information (PI), labelling or packaging, recall of a product or provision of information on the issue to prescribers and consumers of a medicine, including the issuing of Alerts.

Further information about medicines, such as Product Information, Consumer Medicine Information and Alerts can be found on the TGA website at http://www.tga.gov.au

If you wish to receive regular updates about Safety Information on medicines and devices you can subscribe to our notification system. Information about subscribing can be found at http://www.tga.gov.au/newsroom/subscribe-rss.htmThank you in anticipation of your ongoing assistance.

This is an automatically generated acknowledgment letter. There is no need to respond to this correspondence. Any enquiries about this report should be directed to

TGA Health Safety Regulation

adr.reports@health.gov.au

Yours sincerely,

The Adverse Event & Medicine Defect Section
on behalf of the Head
Pharmacovigilance Branch
27/7/2022

PRIVACY STATEMENT

For general privacy information, go to www.tga.gov.au/about/website-privacy.htm

Information provided in your report is collected to assist in the post market monitoring of the safety of therapeutic goods under the *Therapeutic Goods Act 1989* (the Act). All reports are entered into the Therapeutic Goods Administration's (TGA's) Australian Adverse Event Management System. Further information about how the TGA uses adverse event information that is reported to it is available at https://www.tga.gov.au/reporting-adverse-events

The TGA collects personal information in this report to:

- Monitor the safety of medicines and vaccines under the Act.
- Contact the reporter of the adverse event if further information is required.
- Contact representatives of entities that supply therapeutic goods, to discuss reported adverse events.
- Check that the same information has not been received multiple times for the same adverse event.

At times, adverse event information is collected from someone other than the individual to whom the personal information relates. This can occur when an adverse event is reported to a person or an entity other than the TGA (such as a health professional or a hospital or a sponsor), and that person or entity passes the information on to the TGA. In those cases, the TGA will not collect the name and contact details of patients. However, the TGA may collect other information relating to patients including the date of birth or age, gender, weight, initials and information about the relevant adverse event.

Personal information collected in your report may be used or disclosed as permitted under the Privacy Act 1988, including by consent or where the disclosure is required by, or authorised under, a law (for example, under section 61 of the Act). Where a report relates to vaccine events, any personal information in the adverse event report may be disclosed to State and Territory health agencies under section 61(3) of the Act.

Acknowledgement email

Email	[redacted];
Email from	adr.reports@health.gov.au
Email cc	
Subject	TGA Adverse Event (AE) Report s11C [redacted] [SEC=OFFICIAL]
Date and Time	27/07/2022 04:01:22 PM
Attachments	s11C [redacted]

Dear This email is related to your submission to the TGA's Australian Adverse Event Management System (AEMS). Please refer to the attachments.

Australian Government
Department of Health
Therapeutic Goods Administration

[redacted]

Email Address: [redacted]

Dear Sir/Madam

Re: TGA AE Reference: s11C [redacted]
Drug: Covishield Vaxzevria (ChAdOx1-S, Oxford/AstraZenec
Your Reference: [redacted]

Thank you for submi. ng your adverse event report, which was entered into the Therapeutic Goods Administration's (TGA)'s Adverse Event Management System (AEMS) on 27/7/2022. This report has been identified as a duplicate of AE Report Number [redacted] which is the active number for this case. If you submit any further information, please quote the active TGA AE reference number allocated.

please can you confirm the date for 1st and 2nd dose of the Covid vaccine as received by the patient

Please refer to the Privacy Statement at the end of this letter for information about how the TGA handles information of this kind. The TGA does not include any personal information in our database that may have been inadvertently provided in the report, such as patient names but does keep information on the Sender of the report in case any clarification is needed.

The TGA undertakes regular analysis of the AEMS to identify new and emerging safety issues (signals) that may be related to medicines in use in Australia. When a signal is detected, further review is undertaken by the TGA to determine whether any action is required - such as changes to Product Information (PI), labelling or packaging, recall of a product or provision of information on the issue to prescribers and consumers of a medicine, including the issuing of Alerts.

Further information about medicines, such as Product Information, Consumer Medicine Information and Alerts can be found on the TGA website at http://www.tga.gov.au.
If you wish to receive regular updates about Safety Information on medicines and devices you

can subscribe to our notification system. Information about subscribing can be found at http://www.tga.gov.au/newsroom/subscribe-rss.htm.Thank you in anticipation of your ongoing assistance.

This is an automatically generated acknowledgment letter. There is no need to respond to this correspondence. Any enquiries about this report should be directed to adr.reports@health.gov.au.

Yours sincerely,

The Adverse Event & Medicine Defect Section
on behalf of the Head
Pharmacovigilance Branch
27/7/2022

PRIVACY STATEMENT
For general privacy information, go to www.tga.gov.au/about/website-privacy.htm.

Information provided in your report is collected to assist in the post market monitoring of the safety of therapeutic goods under the *Therapeutic Goods Act 1989* (the Act). All reports are entered into the Therapeutic Goods Administration's (TGA's) Australian Adverse Event Management System. Further information about how the TGA uses adverse event information that is reported to it is available at https://www.tga.gov.au/reporting-adverse-events.

The TGA collects personal information in this report to:
• Monitor the safety of medicines and vaccines under the Act.
• Contact the reporter of the adverse event if further information is required.
• Contact representatives of entities that supply therapeutic goods, to discuss reported adverse events.
• Check that the same information has not been received multiple times for the same adverse event.

At times, adverse event information is collected from someone other than the individual to whom the personal information relates. This can occur when an adverse event is reported to a person or an entity other than the TGA (such as a health professional or a hospital or a sponsor), and that person or entity passes the information on to the TGA. In those cases, the TGA will not collect the name and contact details of patients. However, the TGA may collect other information relating to patients including the date of birth or age, gender, weight, initials and information about the relevant adverse event.

Personal information collected in your report may be used or disclosed as permitted under the Privacy Act 1988, including by consent or where the disclosure is required by, or authorised under, a law (for example, under section 61 of the Act). Where a report relates to vaccine events, any personal information in the adverse event report may be disclosed to State and Territory health agencies under section 61(3) of the Act.

Australian Government
Department of Health
Therapeutic Goods Administration

[redacted]

Email Address: [redacted]

Dear Sir/Madam

Re: TGA AE Reference s11C [redacted]
Drug: Covishield Vaxzevria (ChAdOx1-S, Oxford/AstraZenec
Your Reference: [redacted]

Thank you for submitting your adverse event report, which was entered into the Therapeutic Goods Administration's (TGA)'s Adverse Event Management System (AEMS) on 27/7/2022. This report has been identified as a duplicate of AE Report Number [redacted] which is the active number for this case. If you submit any further information, please quote the active TGA AE reference number allocated.

please can you confirm the date for 1st and 2nd dose of the Covid vaccine as received by the patient

Please refer to the Privacy Statement at the end of this letter for information about how the TGA handles information of this kind. The TGA does not include any personal information in our database that may have been inadvertently provided in the report, such as patient names but does keep information on the Sender of the report in case any clarification is needed.

The TGA undertakes regular analysis of the AEMS to identify new and emerging safety issues (signals) that may be related to medicines in use in Australia. When a signal is detected, further review is undertaken by the TGA to determine whether any action is required - such as changes to Product Information (PI), labelling or packaging, recall of a product or provision of information on the issue to prescribers and consumers of a medicine, including the issuing of Alerts.

Further information about medicines, such as Product Information, Consumer Medicine Information and Alerts can be found on the TGA website at http://www.tga.gov.au

If you wish to receive regular updates about Safety Information on medicines and devices you can subscribe to our notification system. Information about subscribing can be found at http://www.tga.gov.au/newsroom/subscribe-rss.htmThank you in anticipation of your ongoing assistance.

PO Box 100 Woden ACT 2606 ABN 40 939 406 804
Phone: 02 6232 8444 Fax: 02 6203 1605 Email: info@tga.gov.au
http://www.tga.gov.au

TGA Health Safety Regulation

TGA Health Safety Regulation

This is an automatically generated acknowledgment letter. There is no need to respond to this correspondence. Any enquiries about this report should be directed to adr.reports@health.gov.au

Yours sincerely,

The Adverse Event & Medicine Defect Section
on behalf of the Head
Pharmacovigilance Branch
27/7/2022

PRIVACY STATEMENT

For general privacy information, go to www.tga.gov.au/about/website-privacy.htm

Information provided in your report is collected to assist in the post market monitoring of the safety of therapeutic goods under the *Therapeutic Goods Act 1989* (the Act). All reports are entered into the Therapeutic Goods Administration's (TGA's) Australian Adverse Event Management System. Further information about how the TGA uses adverse event information that is reported to it is available at https://www.tga.gov.au/reporting-adverse-events

The TGA collects personal information in this report to:

- Monitor the safety of medicines and vaccines under the Act.
- Contact the reporter of the adverse event if further information is required.
- Contact representatives of entities that supply therapeutic goods, to discuss reported adverse events.
- Check that the same information has not been received multiple times for the same adverse event.

At times, adverse event information is collected from someone other than the individual to whom the personal information relates. This can occur when an adverse event is reported to a person or an entity other than the TGA (such as a health professional or a hospital or a sponsor), and that person or entity passes the information on to the TGA. In those cases, the TGA will not collect the name and contact details of patients. However, the TGA may collect other information relating to patients including the date of birth or age, gender, weight, initials and information about the relevant adverse event.

Personal information collected in your report may be used or disclosed as permitted under the Privacy Act 1988, including by consent or where the disclosure is required by, or authorised under, a law (for example, under section 61 of the Act). Where a report relates to vaccine events, any personal information in the adverse event report may be disclosed to State and Territory health agencies under section 61(3) of the Act.

From: ADR Reports
To: ADR Reports
Subject: Update for file upload: s11C [redacted] - [redacted] [SEC=OFFICIAL] CRM:0004098
Date: Friday, 29 July 2022 2:30:48 AM
Attachments: [redacted] file upload.xml

This is an automated email generated from a File Upload

Organisation: [redacted]
Most Recent Information Date:
Report type: Amendment
TGA Case Reference Number: s11C [redacted]
Sender Case Reference: [redacted]
Reported Product Names: Covishield Vaxzevria (ChAdOx1-S, Oxford/AstraZenec

See attached data.

When processing this email, if action is taken in AEMS(i.e.to amend, withdraw or nullify the case), attach this email to the version. If no action is taken, add this email to vaccine file.

```
<?xml version="1.0" encoding="utf-8"?>
<caseadministration>
  <tgacasereference></tg          rence>
  <senderICSRidentifier>[redacted]</senderICSRidentifier>
  <reporttype>Amendment<          pe>
  <mostrecentdat         recentdate>
  <receiveddate>[redacted]000000</receiveddate>
</caseadministra
```

AU-TGA-0000746367

Case details:

Original received date: s47F

Creation date: 27/07/2022

Date sent to WHO:

Involves an unapproved product?:

Unapproved product access:

Modified on: s47F

Decision Reason: Duplicate

Serious ICSR: s47F

Sender details:

NSW Health - Immunisation Unit Health Protection NSW

Sender type: Regional Pharmacovigilance Centre

Sender's ICSR indentifier: 117334076

Patient details:

Patient initials:

Sex: Male

Weight:

Age: 30 (Year)

Date of birth: s47F

State: s47F

Ethnicity:

Reporter details:

Consumer or other non health professional

,

Phone:

Case narrative:

s47F

Reactions:

Preferred term	Onset date	End date	Outcome
Adverse event following immunisation	s47F	s47F	Fatal

Drug information:

Product name	Role characterisation	Action taken
TN010190 COVID-19 Vaccine AstraZeneca - COVID-19 Vaccine AstraZeneca	Suspect	

Dosage/s

Dose	Interval	Dose form	Route of admin	Start date	End date	Batch
		Unknown	Unknown	s47F		Unknown

Tests and procedures: